Recent Updates
Recently added Catalysts
AGEN

Agenus to Report Second Quarter 2013 Financial Results on July 25, 2013; Conference Call to Follow

Key Takeaway: LEXINGTON, Mass., July 18, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its second quarter 2013 financial results before the market opens on July 25, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the li

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
6.2%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
Botensilimab
Phase 1 · Pancreatic Cancer Metastatic

Full Press Release Details

LEXINGTON, Mass., July 18, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its second quarter 2013 financial results before the market opens on July 25, 2013.
Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live call, dial 647-426-1845. The call will also be webcast and will be accessible from the company's website at www.agenusbio.com/webcast/. A replay will be available approximately two hours after the call through midnight Eastern Time on August 25, 2013. The replay number is 416-915-1035, and the access code is 102913. The replay will also be available on the company's website approximately two hours after the live call.
Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Between Agenus and its partners, 21 programs are in clinical development. For more information, please visit www.agenusbio.com.
Last updated: Jul 18, 2013